ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Ligand: Glaxo Receives Priority Review for Eltrombopag's Supplemental NDA

By Victoria Stilwell Ligand Pharmaceuticals Inc. (LGND) said the U.S. Food and Drug Administration granted its partner, GlaxoSmithKline PLC (GSK), priority review of the supplemental new drug application for its eltrombopag drug, which treats thrombocytopenia in patients with chronic hepatitis C virus infection. Eltrombopag, known by the brand name Promacta in the U.S., is currently approved in 89 countries as a treatment for patients with chronic immune thrombocytopenia. Thrombocytopenia is a condition in which a patient's blood has a lower-than-normal number of platelets, allowing mild to serious bleeding to occur inside the body or underneath or from the skin. The drug is used to increase the number of cells that help the blood clot in order to decrease the risk of bleeding. Ligand is a biopharmaceutical company that aims to develop or acquire diverse, royalty-revenue-generating assets and couple them with a lean corporate cost structure. Ligand has also partnerships with companies including Merck & Co. (MRK), Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY). Shares of Ligand closed Tuesday at $17.61 and were inactive in premarket trade. The stock is up 48% so far this year. Write to Victoria Stilwell at Subscribe to WSJ:

Stock News for Merck (MRK)
10/25/201614:02:00Merck Revenue and Profit Rise on Cancer Drugs, Vaccines -- Update
10/25/201613:03:00Stocks Fall on Mixed Earnings Reports
10/25/201612:03:00Stocks Fall on Mixed Earnings Reports
10/25/201610:32:00Stocks Fall on Mixed Earnings Reports
10/25/201610:12:00Stocks Fall on Mixed Earnings Reports
10/25/201609:39:00Stocks Lifted by Upbeat Data, Earnings
10/25/201608:35:00Stocks Lifted by Upbeat Data, Earnings -- 2nd Update
10/25/201608:20:00Merck Profit Rises on Cancer Drugs, Vaccines
10/25/201608:13:00Merck Revenue and Profit Rise on Cancer Drugs, Vaccines
10/25/201606:50:52Current Report Filing (8-k)
10/25/201606:45:00Merck Announces Third-Quarter 2016 Financial Results
10/24/201621:40:00Merck Drug Gets FDA Approval as a First-Line Lung Cancer Treatment
10/24/201620:50:00Merck Drug Gets FDA Approval as a First-Line Lung Cancer Treatment
10/24/201618:04:00FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Metastatic NS...
10/21/201621:57:00FDA Approves Merck’s ZINPLAVA™ (bezlotoxumab) to Reduce Recurrence of...
10/21/201606:45:00Merck’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Ad...
10/19/201607:00:00Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational...
10/17/201617:00:00Merck Research Laboratories Facilities Designated as “Milestones i...
10/14/201608:30:00Merck Launches Biosimilars Clarified, a New Online Educational...
10/10/201602:49:00Merck Announces Recipients of Third Annual €1 Million 'Grant f...

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations